Delivery of GENE-EDITING constructs could be very lucrative for PAB . Something not priced in the share price regarding future potential.
Comment by CEO in 2022
"Patrys could also become a pioneer in the emerging gene-editing payload delivery space, giving it a lead in the gene therapy space, which is expected to see 1,500% growth by 2027, he added."
Delivery of GENE-EDITING constructs could be very lucrative for...
-
- There are more pages in this discussion • 14 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.3¢ |
Change
0.000(0.00%) |
Mkt cap ! $6.172M | |||
| Open | High | Low | Value | Volume |
| 0.4¢ | 0.4¢ | 0.3¢ | $10.97K | 3.626M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 41 | 31554019 | 0.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.4¢ | 27089307 | 15 |
View Market Depth
| Last trade - 16.10pm 04/10/2024 (20 minute delay) ? |
| PAB (ASX) Chart |